سعر كادسيلا 160مجم باودر فيال 2026

Kadcyla 160 mg (trastuzumab emtansine) lyophilised powder in a single-dose vial for intravenous infusion after reconstitution, marketed in Egypt by Roche.

• Single agent for HER2-positive metastatic breast cancer in patients previously treated with trastuzumab and a taxane (prior therapy for metastatic disease or recurrence during/within 6 months of adjuvant therapy).Population: AdultsDailyMed (U.S. National Library of Medicine)
• Adjuvant single-agent treatment of HER2-positive early breast cancer with residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (> 25%) in metastatic breast cancer: nausea, fatigue, musculoskeletal pain, haemorrhage, thrombocytopenia, increased transaminases, headache and constipation.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• None (US label).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: serious hepatotoxicity including liver failure and death; monitor transaminases and bilirubin before starting and before each dose.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning: reductions in left ventricular ejection fraction; evaluate LVEF before and during treatment and withhold for clinically significant decrease.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning: embryo-fetal toxicity; verify pregnancy status and use effective contraception during treatment and for 7 months after the last dose.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, ritonavir, voriconazole)DM1 is metabolised mainly by CYP3A4; avoid strong CYP3A4 inhibitors because DM1 exposure and toxicity may increase; if unavoidable consider delaying Kadcyla until the inhibitor has cleared.DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm: oligohydramnios and its sequelae were reported with trastuzumab, and DM1 can cause embryo-fetal toxicity by its mechanism; exposure during pregnancy or within 7 months before conception can harm the fetus.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; advise not to breastfeed during treatment and for 7 months after the last dose.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Trastuzumab emtansine: The trastuzumab component binds HER2; after internalisation the DM1 (maytansine derivative) component is released and inhibits microtubules, causing cell-cycle arrest and cell death.